Development of cell-cycle inhibitors for cancer therapy

  title={Development of cell-cycle inhibitors for cancer therapy},
  author={Mark A. Dickson and G. K. Schwartz},
  journal={Current Oncology},
  pages={36 - 43}
The cell cycle governs the transition from quiescence through cell growth to proliferation. The key parts of the cell cycle machinery are the cyclin-dependent kinases (CDKS) and the regulatory proteins called cyclins. The CDKS are rational targets for cancer therapy because their expression in cancer cells is often aberrant and their inhibition can induce cell death. Inhibitors of CDKS can also block transcription.Several drugs targeting the cell cycle have entered clinical trials. These agents… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 84 extracted citations


Publications referenced by this paper.
Showing 1-10 of 79 references

Phase i study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (nsclc) [abstract 2060

  • W Siegel–Lakhai, D Rodenstein, J Beijnen, A Gianella–Borradori, J Schellens, D. Talbot
  • Proc Am Soc Clin Oncol 2005;23:. [Available…
  • 2009

Similar Papers

Loading similar papers…